Neurofibromatosis Type 1 Clinical Trials

9 recruiting

Neurofibromatosis Type 1 Trials at a Glance

9 actively recruiting trials for neurofibromatosis type 1 are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Washington D.C., Los Angeles, and Bethesda. Lead sponsors running neurofibromatosis type 1 studies include National Cancer Institute (NCI), Healx Limited, and David Miller.

Browse neurofibromatosis type 1 trials by phase

Treatments under study

About Neurofibromatosis Type 1 Clinical Trials

Looking for clinical trials for Neurofibromatosis Type 1? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neurofibromatosis Type 1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neurofibromatosis Type 1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

Neurofibromatosis Type 1Neurofibroma
National Cancer Institute (NCI)110 enrolled1 locationNCT06880991
Recruiting

Familial Investigations of Childhood Cancer Predisposition

Hereditary Breast and Ovarian CancerHodgkin LymphomaAdrenocortical Carcinoma+30 more
St. Jude Children's Research Hospital1,500 enrolled1 locationNCT03050268
Recruiting

Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

Neurofibromatosis Type 1
AstraZeneca200 enrolled9 locationsNCT07221331
Recruiting
Not Applicable

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Neurofibromatosis Type 1
National Cancer Institute (NCI)70 enrolled2 locationsNCT06507748
Recruiting
Phase 2

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

Neurofibromatosis Type 1
Healx Limited25 enrolled13 locationsNCT06541847
Recruiting

FARD (RaDiCo Cohort) (RaDiCo-FARD)

PemphigusNeurofibromatosis Type 1Ichthyosis+6 more
Institut National de la Santé Et de la Recherche Médicale, France900 enrolled15 locationsNCT05954416
Recruiting

Neurofibromatosis Type 1 Tumor Early Detection Study

Malignant Peripheral Nerve Sheath TumorNeurofibromatosis Type 1Neurofibromatosis 1+4 more
David Miller1,000 enrolled1 locationNCT06515860
Recruiting
Not Applicable

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

Neurofibromatosis Type 1
Nicole Baca15 enrolled1 locationNCT04763109
Recruiting
Phase 3

STRENGTH Study: Supplement Treatment Evaluation of L-carnitine for Muscle Fatigue and Weakness in Children with Neurofibromatosis Type 1

Neurofibromatosis Type 1
Royal North Shore Hospital40 enrolled1 locationACTRN12624000781549